|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0466 - 0.0466|
|52 Week Range||0.0210 - 0.0650|
|Beta (5Y Monthly)||-0.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
* Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.
EPALINGES, SWITZERLAND / ACCESSWIRE / June 11, 2020 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that its subsidiary, Mymetics SA, has received the confirmation to receive access to the European vaccine infrastructure TRANSVAC2 services for the evaluation and development of virosome-based vaccines against Covid-19, the disease caused by SARS-CoV-2. Since April, Mymetics has started the investigation for the rapid development of a Covid-19 virosome-based vaccine and is thereby partnering with leading academic institutions to start evaluating the most suitable antigens.
Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy. The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice. EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.